The Transcription Factor IRF4 Determines the Anti-Tumor Immunity of CD8+ T cells
Four TIL populations from B16-F10 melanoma were analyzed by scRNA-seq, including adoptively transterred anti-tumor CD8+ Pmel-1 T cells that were transduced with IRF4 (sample 1, IRF4_Pmel) or GFP control (Sample 3, Ctrl_Pmel), and CD45+ endogenous TILs from either the IRF4 group (Sample 2, IRF4_TILs) or Ctrl group (Sample 4, Ctrl_TILS). Overall design: scRNAseq analysis of TILs from B16-F10 melanoma was performed.